Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 293

1.

The clinical significance of Psoriasin for non-small cell lung cancer patients and its biological impact on lung cancer cell functions.

Hu M, Ye L, Ruge F, Zhi X, Zhang L, Jiang WG.

BMC Cancer. 2012 Dec 10;12:588. doi: 10.1186/1471-2407-12-588.

2.

Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.

Pesta M, Kulda V, Fiala O, Safranek J, Topolcan O, Krakorova G, Cerny R, Pesek M.

Anticancer Res. 2012 Nov;32(11):5003-10.

PMID:
23155271
3.

Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.

Zhao ZH, Wang SF, Yu L, Wang J, Chang H, Yan WL, Zhang J, Fu K.

Lung Cancer. 2008 Oct;62(1):113-9. doi: 10.1016/j.lungcan.2008.02.014. Epub 2008 Jun 11.

PMID:
18550205
4.

Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition.

Sun M, Liu XH, Wang KM, Nie FQ, Kong R, Yang JS, Xia R, Xu TP, Jin FY, Liu ZJ, Chen JF, Zhang EB, De W, Wang ZX.

Mol Cancer. 2014 Mar 21;13:68. doi: 10.1186/1476-4598-13-68.

5.

High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients.

Wei LX, Zhou RS, Xu HF, Wang JY, Yuan MH.

Tumour Biol. 2013 Apr;34(2):941-6. doi: 10.1007/s13277-012-0629-3. Epub 2012 Dec 22.

PMID:
23264086
6.

Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study.

Li H, Zhou RJ, Zhang GQ, Xu JP.

Tumour Biol. 2013 Jun;34(3):1807-12. doi: 10.1007/s13277-013-0720-4. Epub 2013 Mar 8.

PMID:
23471668
7.

mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.

Wang L, Yue W, Zhang L, Zhao X, Wang Y, Xu S.

Surg Today. 2012 May;42(5):419-25. doi: 10.1007/s00595-011-0028-1. Epub 2011 Nov 30.

PMID:
22127531
8.

UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer.

Zhao L, Jiang L, Wang L, He J, Yu H, Sun G, Chen J, Xiu Q, Li B.

J Cancer Res Clin Oncol. 2012 Nov;138(11):1951-61. doi: 10.1007/s00432-012-1275-2. Epub 2012 Jul 4.

PMID:
22760214
9.

Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer.

Zhang Y, Yu JH, Lin XY, Miao Y, Han Y, Fan CF, Dong XJ, Dai SD, Wang EH.

Virchows Arch. 2011 Sep;459(3):255-63. doi: 10.1007/s00428-011-1135-5. Epub 2011 Aug 5.

PMID:
21818639
10.

Down-regulation of NKD1 increases the invasive potential of non-small-cell lung cancer and correlates with a poor prognosis.

Zhang S, Wang Y, Dai SD, Wang EH.

BMC Cancer. 2011 May 20;11:186. doi: 10.1186/1471-2407-11-186.

11.

Clinical significance of annexin II expression in human non-small cell lung cancer.

Jia JW, Li KL, Wu JX, Guo SL.

Tumour Biol. 2013 Jun;34(3):1767-71. doi: 10.1007/s13277-013-0715-1. Epub 2013 Mar 14.

PMID:
23494179
12.

Knockdown of S100A7 reduces lung squamous cell carcinoma cell growth in vitro and in vivo.

Liu G, Wu Q, Liu G, Song X, Zhang J.

Int J Clin Exp Pathol. 2014 Oct 15;7(11):8279-89. eCollection 2014.

13.

Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival.

Zhou CH, Ye LP, Ye SX, Li Y, Zhang XY, Xu XY, Gong LY.

J Exp Clin Cancer Res. 2012 Mar 3;31:18. doi: 10.1186/1756-9966-31-18.

14.

Expression and significance of hypoxia inducible factor-1α and lysyl oxidase in non-small cell lung cancer.

Ping W, Jiang WY, Chen WS, Sun W, Fu XN.

Asian Pac J Cancer Prev. 2013;14(6):3613-8.

15.

Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer.

Han KY, Gu X, Wang HR, Liu D, Lv FZ, Li JN.

Tumour Biol. 2013 Apr;34(2):821-5. doi: 10.1007/s13277-012-0612-z. Epub 2012 Dec 11.

PMID:
23229099
16.

Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas.

Zhan P, Shen XK, Qian Q, Wang Q, Zhu JP, Zhang Y, Xie HY, Xu CH, Hao KK, Hu W, Xia N, Lu GJ, Yu LK.

Oncol Rep. 2012 Apr;27(4):1072-8. doi: 10.3892/or.2011.1605. Epub 2011 Dec 21.

17.

Clinical significance of SH2B1 adaptor protein expression in non-small cell lung cancer.

Zhang H, Duan CJ, Chen W, Wang SQ, Zhang SK, Dong S, Cheng YD, Zhang CF.

Asian Pac J Cancer Prev. 2012;13(5):2355-62.

18.

ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.

Ni SS, Zhang J, Zhao WL, Dong XC, Wang JL.

Tumour Biol. 2013 Jun;34(3):1813-8. doi: 10.1007/s13277-013-0721-3. Epub 2013 Mar 9.

PMID:
23475633
19.

MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5.

Liu XH, Lu KH, Wang KM, Sun M, Zhang EB, Yang JS, Yin DD, Liu ZL, Zhou J, Liu ZJ, De W, Wang ZX.

BMC Cancer. 2012 Aug 9;12:348. doi: 10.1186/1471-2407-12-348.

20.

Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.

Wu YH, Cheng YW, Chang JT, Wu TC, Chen CY, Lee H.

Cancer. 2007 Jul 1;110(1):215-23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk